Publikationen in Zusammenarbeit mit Forschern von Hospital Universitario Virgen Macarena (18)

2023

  1. Direct-acting oral anticoagulants in antiphospholipid syndrome: A systematic review

    Medicina Clinica, Vol. 161, Núm. 2, pp. 65-77

2021

  1. Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

    BMC Infectious Diseases, Vol. 21, Núm. 1

  2. Modifications of CD4 T cells, CD4/CD8 ratio and serum levels of soluble CD14 in HIV-HCV-coinfected patients after sustained HCV response induced by direct-acting antiviral agents: influence of liver cirrhosis

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 40, Núm. 9, pp. 1863-1871

2019

  1. Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects

    Journal of Neuroimmune Pharmacology, Vol. 14, Núm. 3, pp. 413-422

2018

  1. Diagnosis and empirical treatment for community-acquired pneumonia in special situations: immunocompromised HIV negative and elderly patients

    Medicine (Spain), Vol. 12, Núm. 53, pp. 3168-3173

  2. Diagnostic and therapeutic protocol for community-acquired pneumonia

    Medicine (Spain), Vol. 12, Núm. 53, pp. 3162-3167

  3. Diagnostic and therapeutic protocol for pleural infections

    Medicine (Spain), Vol. 12, Núm. 54, pp. 3231-3234

  4. Unsolicited consultation by infectious diseases specialist improves outcomes in patients with bloodstream infection: A prospective cohort study

    Journal of Infection, Vol. 77, Núm. 6, pp. 503-508

2017

  1. Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 3, pp. 487-494

2015

  1. Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 9, pp. 1879-1884

2013

  1. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis

    Clinical Infectious Diseases, Vol. 56, Núm. 11, pp. 1646-1653

2012

  1. Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients

    AIDS, Vol. 26, Núm. 13, pp. 1721-1724

  2. Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis

    Clinical Infectious Diseases, Vol. 55, Núm. 12, pp. 1719-1726

2008

  1. Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients

    AIDS, Vol. 22, Núm. 8, pp. 923-930

  2. Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen

    Journal of Antimicrobial Chemotherapy, Vol. 62, Núm. 4, pp. 793-796

  3. Liver toxicity of antiretroviral combinations including atazanavir/ ritonavir in patients co-infected with HIV and hepatitis viruses: Impact of pre-existing liver fibrosis

    Journal of Antimicrobial Chemotherapy, Vol. 61, Núm. 4, pp. 925-932

2007

  1. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients

    Journal of Antimicrobial Chemotherapy, Vol. 60, Núm. 6, pp. 1347-1354

  2. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients

    Antiviral Therapy, Vol. 12, Núm. 8, pp. 1225-1235